|View printer-friendly version|
Array BioPharma to Host Analyst and Investor Day Featuring Distinguished Clinical Investigators
The meeting will feature a group of distinguished independent experts who will share their perspectives on the general landscape of cancer treatments in development and Array’s drug candidates.
A noted medical oncologist will provide an update on MEK inhibitors as cancer therapeutics including Array’s partnered drugs, selumetinib and MEK162:
Director, Drug Development Program
Sarah Cannon Research Institute
And leading hematologists will discuss data presented on ARRY-520, a KSP
inhibitor, and ARRY-614, a dual p38/Tie2 inhibitor, at the
Professor, Department of Lymphoma/Myeloma
Professor of Medicine and Chief, Section of Myelodysplastic Syndrome
The Analyst and Investor Day is open to members of the professional
investment community. For information on attending the event, please
The live webcast of the meeting, including slides, will also be available in the Investor Relations section of Array’s website: http://investor.arraybiopharma.com/phoenix.zhtml?c=123810&p=irol-EventDetails&EventId=4241464.
Please log in approximately 10 minutes prior to the presentation to ensure a timely connection. An archived version will also be available on the Company’s website for a limited time after the event.
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193